Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
The acquisition of Pharmatech supports USPs commitment to strengthen the supply chain of quality medicines, builds on our longstanding work with regulators and manufacturers globally to solve some of the most critical and challenging problems in the ...
read more
Univercells Technologies, a provider of novel biomanufacturing technologies for flexible and scalable viral vector production, has formed a partnership with VectorBuilder, a vector design, optimization and manufacturing company. Univercells ...
read more
NewAge Industries, the manufacturer of AdvantaPure® high purity tubing products, has expansion plans underway – again – at its corporate facility in southeastern Pennsylvania. The project will add over 3,000 sq. ft. of ISO Class 7 certified ...
read more
Protagen Protein Services (PPS) announced that it will merge with GeneWerk, an Ampersand portfolio company. With the addition of GeneWerk’s unique capabilities in vector safety, characterization, and functionality analysis, PPS will complement its ...
read more
AGC Biologics, a biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the signing of a purchase agreement for a state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, Colorado, ...
read more
OSE Immunotherapeutics and Cenexi, a French contract development and manufacturing organization (CDMO), announced the signature of an agreement whereby Cenexi will manufacture clinical batches of CoVepiT, OSE Immunotherapeutics' vaccine candidate ...
read more
HERMES PHARMA, previously a division of HERMES Arzneimittel GmbH, announced a separate legal entity named HERMES PHARMA GmbH. The forward-looking change will see both HERMES PHARMA GmbH and HERMES Arzneimittel GmbH operating independently but ...
read more
Lonza announced new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over $22 million, will allow Lonza to provide a smoother transition from small-scale to...
read more
Novasep, a supplier of services and technologies for the life sciences industry, announced a €6.1 million investment at its Mourenx facility(Pyrénées-Atlantiques – France). This investment will modernize its API manufacturing facility.
read more
CellPoint, a cell therapy company developing CAR-T therapeutics for use at the point-of-care, announces an agreement with Lonza's Personalized Medicine Business Unit to employ Lonza's Cocoon® Platform for clinical manufacturing of CellPoint's CAR-T ...
read more
Breckenridge Pharmaceutical, Inc. announced the signing of a multi-product agreement with Aggrega Pharma, LLC. under which Aggrega will develop, manufacture and supply pharmaceutical products for marketing, sale and distribution by Breckenridge.
read more
Chemomab Therapeutics,Ltd., a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a global Biopharmaceutical Contract Development ...
read more
Genezen Laboratories, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has broken ground on a new multiphase master...
read more
Coriolis Pharma, a globally operating service provider in formulation research and development of biopharmaceutical drugs, announced the expansion of its ATMP development facilities under biosafety level S2 (BSL2).
read more
Danaher Corporation announced that Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or ...
read more